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Background: Rheumatoid arthritis has seen a significant increase in both incidence and prevalence 9 
and its treatments show limited efficiency due to their undesirable effects on patient health. 10 
Therefore, major interests lie in the development of treatments with drugs derived from plants or 11 
other natural sources with little adverse effects as an alternative to current treatments. 12 
Hypothesis/Purpose: The present study evaluates the therapeutic effects of glucosamine against 13 
rheumatoid arthritis in combination with hyaluronic acid, resin extract of Boswellia serrata or a 14 
bark extract of Salix alba on an animal model. We suggest that combinations with plants could 15 
improve the attenuation of arthritis symptoms and articular inflammation. 16 
Study design: We used Freund’s complete adjuvant on rats as models of rheumatoid arthritis. 17 
Individuals were separated into eight experimental groups: a control group without arthritis, one 18 
with arthritis and without treatment, and six other groups receiving a daily therapeutic treatment 19 
from days 14 to 29. 20 
Methods: Hind-paw thickness and arthritis scores were measured at days 0, 3, 6 and 9 post-21 
induction, and then every day from days 12 to 29 with a digital caliper and a score system 22 
respectively. At the end of the treatment, the mRNA content of three pro-inflammatory cytokines 23 
from cartilage was measured using real-time PCR. The total antioxidant activity was evaluated with 24 
an Antioxidant Assay Kit.  25 
Results: Treatments with Boswellia serrata and Salix alba (Glu+Hyal A+Bosw, Glu+Bosw+Sal, 26 
Glu+Bosw and Glu+Hyal A+Sal) saw significant reductions in hind-paw thickness and arthritis 27 
scores at the end of the experiment when compared to the untreated group. Expression of pro-28 
inflammatory gene IL 17A was also reduced, but only the Glu+Hyal A+Sal combination 29 
significantly decreased the expression of IL-1β and TNF-α. The total antioxidant activity in blood 30 
plasma significantly increased in groups treated with plant extracts. 31 
Conclusion: The addition of Boswellia serrata and/or Salix alba attenuates clinical signs of 32 
rheumatoid arthritis in Freund’s complete adjuvant-induced arthritis in rats likely due to both their 33 
anti-inflammatory and antioxidant properties.  34 
 35 
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Rheumatoid arthritis is an inflammatory autoimmune disorder. Its incidence and prevalence 44 
increase considerably all over the world. In North America and North-European countries, its 45 
incidence varies between 20 and 50 per 100,000 population (Fazal et al., 2018). It causes 46 
inflammation in joints that leads to pain, stiffness, swelling and cartilage damage (Arthritis Society, 47 
2018). Current treatments do not usually regenerate damaged cartilage or slow the degeneration, 48 
but relieve symptoms instead (Arthritis Society, 2018). Treatments using steroids, nonsteroidal 49 
anti-inflammatory drugs (NSAIDs), topical anti-inflammatories, biological agents (TNF-α and IL-50 
1 antagonists), acetaminophen and injection of corticosteroids and hyaluronic acid are used against 51 
joint diseases but show limited efficiency due to their undesirable adverse effects on patient health 52 
(Fan et al., 2005; Zheng et al., 2014). These pharmaceutical drugs can provoke gastrointestinal 53 
disturbances (ulcers and perforations), cardiovascular complications, reproductive toxicity, loss of 54 
bone mass, and topical applications can be of no benefit when the target joints are too deep (Fan et 55 
al., 2005; Umar et al., 2014; Zheng et al., 2014). Due to these limitations, there is an important 56 
incentive for the development of biomolecules derived from plants or natural sources without 57 
adverse effects as an alternative to NSAIDs and other treatments. Among these biomolecules, 58 
glucosamine sulfate (GS), hyaluronic acid (HA), resin extracts of indian frankincense (Boswellia 59 
serrata Roxb. Ex Colebr., BS) and bark extracts of white willow (Salix alba L., SA) are four natural 60 
ingredients that are individually considered as efficient against arthritis by regulatory agencies (for 61 
example see the monograph of Natural and Non-prescription Health Products Directorate 62 
(NNHPD) in Canada (Health Canada, 2018)).  63 
GS is an important component of cartilage and is naturally synthesized in the body. This amino 64 
monosaccharide stimulates the biosynthesis of glycosaminoglycan chains, giving the cartilage its 65 
strength, flexibility and elasticity, all the while possessing anti-inflammatory properties (Singh et 66 
al., 2007). HA is a large viscoelastic glycosaminoglycan present in the synovial fluid, and is 67 
responsible for its viscoelastic properties (Moreland, 2003). It also confers good protective 68 
properties including shock absorption, protective coating of the articular cartilage surface, and 69 
lubrication. BS and SA have both anti-inflammatory and analgesic properties due to the presence 70 
of boswellic acid and salicin respectively (Kimmatkar et al., 2003; Shara and Stohs, 2015). 71 
Boswellic acid reduces pain and swelling, has antioxidant and free radical-scavenging properties, 72 
and appears as a potential new treatment of inflammatory disorders like rheumatoid arthritis and 73 
osteoarthritis (Umar et al., 2014). It reduces glycosaminoglycan degradation, keeping the cartilage 74 
in good condition unlike NSAIDs that can induce the disruption of the glycosaminoglycan 75 
synthesis, accelerating articular damage (Kimmatkar et al., 2003). Salicin has anti-inflammatory 76 
and anabolic effects, as shown in canine joints (Shara and Stohs, 2015). Benefits of these natural 77 
ingredients have so far only been studied separately, and their potential synergistic effects need to 78 
be assessed, as a combination of ingredients can improve their therapeutic effects at the low doses 79 
recommended by the health regulation agencies.  80 
Thus, the aim of this study is to examine the potency of different combinations of natural 81 
ingredients to limit arthritis symptoms and articular inflammation on an animal model of 82 
rheumatoid arthritis. In this context, we used rats previously injected with Freund’s complete 83 
adjuvant. Therefore, quantifying the modulation of inflammation might represent the extent to 84 
which hyaluronic acid, Boswellia serrata or Salix alba extract combined to glucosamine can 85 
improve the therapeutic efficiency of glucosamine alone.   86 
 87 
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Materials and methods 89 
Animals  90 
Adult female Lewis rats (10 weeks old) were obtained from Charles River Laboratories (Montreal, 91 
QC, Canada). Animals were kept at Université du Québec à Rimouski (UQAR) in controlled 92 
experimental conditions (23 ± 1°C, relative humidity 40-60%, 12h light/dark cycles, water and 93 
LabDiet 5002 ad libitum). They were acclimated during 1 week before the experiment. Animal 94 
manipulation was conducted in accordance with the Institutional Animal Care Committee of 95 
Université du Québec à Rimouski (protocol #CPA-66-16-178).  96 
Adjuvant Induction  97 
Arthritis was induced by subcutaneous injection of 60 µl of Freund’s adjuvant, a solution of 98 
Mycobacterium tuberculosis inactivated by heat (Chondrex, Inc. Redmond, WA, USA, 10 mg/ml), 99 
at the base of the tail. First symptoms of arthritis appeared 12 days after induction. 100 
Evaluation of Clinical Signs of Arthritis 101 
Arthritis symptoms were examined at days 0, 3, 6 and 9 post-induction, and then every day from 102 
days 12 to 29. Hind-paw thickness was measured with a digital caliper. Arthritis scores were 103 
determined by a score system: for each of hind paw, a scale of 0-4; 0, no macroscopic sign; 1, 104 
irritation (swelling and redness) at one joint; 2, irritation at more than one joint and/or ankles; 3, 105 
irritation at many joints and moderate swelling at the ankle; 4, irritation at many joints and severe 106 
swelling at the ankle. For each forepaw, a scale of 0-3 was used; 0, no macroscopic sign; 1, irritation 107 
at one joint; 2, irritation at many joints and/or wrist; 3, irritation at all joints and moderate to severe 108 
swelling at the wrist. The final score was calculated by adding the individual score of each paw for 109 
a maximal result of 14 (Aghazadeh-Habashi et al., 2014). 110 
Therapeutic Ingredient Administration 111 
Rats were separated randomly in eight different groups: a control group without arthritis (control), 112 
another one with arthritis and no treatment (CFA, Freund’s complete adjuvant) and six other groups 113 
receiving a daily therapeutic treatment from days 14 to 29. The temporal experimentation plan of 114 
animal manipulations is presented in Fig 1. Six therapeutic treatments were administered to the 115 
rats: GS (Glu); GS and HA (Glu+Hyal A); GS, HA and BS (Glu+Hyal A+Bosw); GS, HA and SA 116 
(Glu+Hyal A+Sal); GS and BS (Glu+Bosw); and GS, BS and SA (Glu+Bosw+Sal).  117 
Each ingredient was administered individually, even when the therapeutic treatment had many 118 
compounds, and orally (back of the mouth) with a pipette. For each ingredient, the daily dose 119 
corresponded to the maximal recommended dosage for humans by Natural and Non-prescription 120 
Health Products Directorate (NNHPD) of Health Canada (2014) in its monograph titled «Multiple 121 
ingredient joint health products». The dosages for rats were calculated considering an average 122 
human weight of 60 kg (weight approved by Food and Drugs Administration (FDA) for safety 123 
studies) and a normalization that takes into account the body surface (Reagan-Shaw et al., 2007). 124 
The daily dosages are presented in Table 1. This formula represents the allometric conversion:  125 
Animal equivalent dose (mg/kg) = human equivalent dose (mg/kg) / [Factor km rat/Factor km 126 
human]  127 
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where   Factor km = body mass (kg) / total body surface (m2) 128 
and   km rat = 6  129 
km human = 37 130 
Solutions of therapeutic ingredients were made daily as follows: GS (Novel Ingredients, NJ, USA), 131 
200 mg/mL of water; HA from bacterial fermentation (A&A Pharmachem Inc, Ontario, Canada), 132 
10 mg/mL of water; BS (40% of boswellic acid) (Dolcas Biotech, NJ, USA), 200 mg/mL of organic 133 
canola oil; SA (25% of salicin) (Novel Ingredients, NJ, USA), 50 mg/ml of water. Due to the 134 
specificity of BS’s solvent, all rats in groups not receiving treatment with BS received an equivalent 135 
daily volume of canola oil (100 µL). At the end of the experiment, all rats were euthanized by 136 
injection of a lethal dose of pentobarbital. A blood sample and knee cartilage of the two hind paws 137 
were collected. Plasma was extracted, samples were rapidly frozen by liquid nitrogen and preserved 138 
at -80 °C for future assays.  139 
Expression of Pro-Inflammatory Genes and Cartilage Degradation 140 
Cartilage samples were reduced to powder with liquid nitrogen. RNA was extracted with Pure 141 
LinkRNA Mini Kit (Life Technologies, CA, USA; cat# MAN0000406, protocol with Trizol and 142 
DNase). Extraction purity was validated using spectrophotometry (absorbance ratio 260 / 280 nm). 143 
Inverse transcription was carried out on 400 ng of RNA for each extract according to high capacity 144 
cDNA reverse transcription kit method (Applied Biosystems, CA, USA; cat# 4368814). Obtained 145 
complementary DNA was used for real-time polymerase chain reaction essays (rt-PCR). Real-time 146 
PCR was performed with SensiFAST SYBR No-ROX kit from Bioline and with a LightCycler 480 147 
from Roche (Mississauga, Canada). Three cytokines responsible for pro-inflammatory processes 148 
were targeted: interleukin-1 (IL-1β), interleukin-17 (IL-17A) and tumor necrosis factor (TNF-α). 149 
Primer sequences used for amplification are shown in Table 2. and were purchased from Sigma 150 
Aldrich (Oakville, Ontario, Canada). Gene expression was quantified by Cycle Treshold method 151 
(Ct). Amplification standard curve of each gene was performed and the specific amplification 152 
efficiency was verified with a minimal threshold of 1,8 (maximum 2). In order to standardize and 153 
compare the different assays, a pool of cDNAs of all groups was used as an internal calibrator. 154 
Gene quantification values were expressed relative to the gene quantification of two endogenous 155 
references, β-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Ratio expressions 156 
for both references were similar; only results with the expression of β-actin are shown in this study. 157 
The specificity of PCR products was confirmed by migration on electrophoresis gel and melting 158 
curve analysis.  159 
Total Antioxidant Activity 160 
Total antioxidant activity of plasma was measured with the Antioxidant Assay Kit from Cayman 161 
Chemical (Ann Arbor, MI, USA; cat# 709001). Values were expressed in equivalent values of 162 
Trolox.  163 
Statistical Analysis 164 
The results are shown as mean ± standard errors. They were analyzed using JMP Pro (SAS, Cary, 165 
NC, USA). One-way ANOVAs followed by a Tukey’s test were used to determine if there were 166 
differences between groups. The homogeneity of variance and the normality of data were tested 167 
using a Shapiro-Wilk and Bartlett’s test respectively. Two groups were statistically different if the 168 
p-value is lower than 0,05 169 
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Effect on Clinical Signs of Arthritis  172 
Measurement of hind-paw thickness and evaluation of the arthritis scores quantified the 173 
development of clinical symptoms in rats during the experiment. First signs of arthritis appeared 174 
on day 12 after the injection of Freund’s adjuvant (Fig. 2). On day 19, hind-paw thickness of the 175 
CFA group increased significantly (6.19 ± 0.90 mm) compared to the control group (3.59 ± 0.17 176 
mm). Treatments with combinations of three ingredients (Glu+Hyal A+Bosw; Glu+Hyal A+Sal; 177 
Glu+Bosw+Sal) and Glu+Bosw limited articular swelling and significantly reduced hind-paw 178 
thickness during the treatment. At the end of the experiment (day 29), hind-paw thickness of these 179 
groups was significantly inferior to the CFA group (Fig. 2A) (Glu+Hyal A+Sal: 4.50 ± 0.78 mm; 180 
Glu+Hyal A+Bosw: 4.35 ± 0.65 mm; Glu+Bosw: 3.85 ± 0.63 mm; Glu+Bosw+Sal: 3.84 ± 0.48 181 
mm; CFA: 5.84 ± 0.97 mm, p < 0.05). Severity of arthritis was evaluated by visual inspection 182 
through a score system which reflects the number of affected joints and the swelling intensity in 183 
digits and wrists/ankles. Arthritis scores increased from days 12 to 18 post-induction. At day 18, 184 
the maximal score was reached for the CFA group (Fig. 2B). A significant decrease of arthritis 185 
scores was observed for Glu+Hyal A+Bosw, Glu+Bosw+Sal, Glu+Bosw and Glu+Hyal A+Sal 186 
treatments in comparison to the CFA group at days 23, 25, 26 and 27 respectively. At day 29, 187 
arthritis scores of these groups were significantly inferior to the CFA group (Glu+Hyal A+Bosw: 188 
5.33 ± 3.61; Glu+Bosw+Sal: 5.17 ± 4.07; Glu+Bosw: 5.17 ± 3.06; Glu+Hyal A+Sal: 5.83 ± 2.14; 189 
CFA: 11.42 ± 2.31, p < 0.01). Treatments with only glucosamine (Glu) and both glucosamine and 190 
hyaluronic acid (Glu+Hyal A) yielded no significant improvement of the clinical symptoms. The 191 
hind-paw conditions of each group at the end of the experiment are shown in Fig. 3.  192 
Effect on Expression of Pro-inflammatory and Cartilage Degradation Genes  193 
At day 29, expression of cytokines IL-17A and IL-1β of CFA group was significantly greater than 194 
the control group (Fig. 4A-B). Glu+Hyal A+Sal treatment significantly reduced the expression of 195 
IL-17A and IL-1β compared to the CFA group. A decrease in the expression of IL-17A by 196 
Glu+Bosw and Glu+Bosw+Sal was also noticed. Glu+Hyal A+Bosw tended to limit IL-17A and 197 
IL-1β expressions, but the difference with the CFA group wasn’t significant. TNF-α expression of 198 
CFA group was not superior to the control group (Fig 4C). Glu+Hyal A+Sal treatment inhibited 199 
TNF-α compared to both the control and the CFA group.  200 
Effect on Total Antioxidant Activity of Plasma 201 
Fig. 5 shows that all treatments with combinations of two or three ingredients significantly 202 
increased the antioxidant capacity of blood, compared to the CFA group and control group 203 
(Glu+Hyal A: 4,16 ± 0,14; Glu+Hyal A+Bosw: 4,51 ± 0,07; Glu+Hyal A+Sal: 3,81 ± 0,18; 204 
Glu+Bosw: 4,71 ± 0,27; Glu+Bosw+Sal: 3,80 ± 0,06; CFA: 2,87 ± 0,16; Heal: 3,24 ± 0,13, p < 205 
0,05). 206 
 207 
Discussion  208 
The aim of this study was to evaluate if glucosamine sulfates therapeutic effects against rheumatoid 209 
arthritis could be enhanced through a combination with hyaluronic acid, Boswellia serrata extract 210 
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or Salix alba extract. First symptoms of arthritis were evaluated by measuring the thickness of hind 211 
paws and by a visual examination (arthritis score). The combinations with BS and/or SA 212 
significantly reduce hind-paw thickness and arthritis scores during the treatment. Salix nigra bark 213 
methanol extract (100 mg/kg/day) has inhibited the progression of collagen-induced arthritis in rats 214 
at the end of the experiment by leaving arthritis scores and paw swelling close to healthy control 215 
(Sharma et al., 2011). In other studies, boswellic acid extract (total acid content: 93 ± 3%) from BS 216 
(250 mg/kg) was more efficient than glucosamine (250 mg/kg) to reduce inflammation in 217 
Mycobacterium-induced arthritis in acute and chronic model of inflammation in rats (Singh et al., 218 
2007). Furthermore, in the same study, the combination of these two ingredients have shown a 219 
significant synergistic effect on chronic inflammation with a dose of 125 mg/kg for boswellic acid 220 
and 125 mg/kg for glucosamine. We suspect that the synergistic effect result from the combination 221 
of the different metabolic targets by which the bioactive molecules reduce inflammation. Anti-222 
arthritic proprieties of each ingredient might have amplified the therapeutic effect of treatments. 223 
Glucosamine and hyaluronic acid have major structural roles in articular cartilage. Glucosamine 224 
stimulates the production of glycosaminoglycans that provide strength and elasticity to cartilage 225 
and connective tissues by holding joint tissue together and giving shock-absorbing properties 226 
(Singh et al., 2007). HA is a component of the synovial fluid and confers viscosity, as well as shock-227 
absorbing and lubricating abilities (Moreland, 2003)., Boswellia spp. and Salix spp.  do indeed 228 
produce active compounds like boswellic acid and salicin that show anti-inflammatory activities 229 
(Kimmatkar et al., 2003; Shara and Stohs, 2015). They directly target the inflammatory mediators 230 
such as interleukins and metalloproteinases (Umar et al., 2014; Sharma et al., 2011). BS extracts 231 
inhibit the 5-lipoxygenase which contributes to the progression of chronic inflammation through 232 
greater recruitment of white blood cells at inflammatory sites (Kimmatkar et al., 2003). BS and SA 233 
also have ROS-scavenging properties and can have a certain control on antioxidant enzymes 234 
(Sharma et al., 2011; Umar et al., 2014). Many studies, including ours, have concluded that 235 
combinations of glucosamine with either BS and/or SA are a promising strategy for limiting clinical 236 
signs of arthritis (Umar et al., 2014; Sharma et al., 2011; Kimmatkar et al., 2003).In our study, GS 237 
alone or in combination with HA did not result in any improvement of the arthritis symptoms. A 238 
previous study demonstrated that glucosamine can inhibit swelling in joints and reduce arthritic 239 
scores in rat adjuvant arthritis (Hua et al., 2005). However, the dose that they used was much higher 240 
than the equivalent dose usually administered to humans. It happens frequently in animal studies 241 
that the administered dose is higher than the recommended equivalent (when corrected for 242 
allometry) for humans. These doses could not be applied to humans according to the severe 243 
legislation in different countries. Maximal dosages of natural products are highly regulated to avoid 244 
adverse effects. We can therefore suspect that maximal recommended dosages for humans may not 245 
result in significant inhibition of the clinical signs of arthritis in both rats and humans. For example, 246 
a meta-analysis including 10 trials with an average of at least 100 patients concluded that 247 
glucosamine (1500 mg/kg/day: recommended dosage) was not effective against osteoarthritis, 248 
having no relevant clinical effect on pain or structure of affected joints (Wandel et al., 2010). Then, 249 
it becomes clearly advantageous to use combinations of ingredients to compensate for the small 250 
effect of a single ingredient (at recommended doses), and to rely on the synergetic effect of 251 
combinations without exceeding the recommended dosages of individual biomolecules.  252 
Inhibition of pro-inflammatory cytokines can reduce clinical signs of arthritis. We therefore 253 
analyzed the mRNA content of three pro-inflammatory cytokines. IL-1β and TNF-α, two major 254 
pro-inflammatory cytokines, are both known to be present at high concentrations in serum and 255 
synovial fluid in patients with RA (Umar et al., 2014). IL-1β and TNF-α stimulate their own 256 
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production and the production of other cytokines, amplifying the inflammation process (Moreland, 257 
2003) and contribute synergistically to produce the inflammasome (Gaffen, 2009).  258 
In our study, TNF-α and IL-1β expression was significantly reduced by only Glu+Hyal A+Sal. A 259 
previous study, on synovial-cell cultures from patients with RA, demonstrated that blocking the 260 
activity of TNF-α significantly reduced the production of IL-1, IL-6 and IL-8 (Butler et al., 1995). 261 
Thus, blocking TNF-α may have a greater overall effect on inflammation than only blocking IL-1. 262 
Moreover, we suspect that this reduction of TNF-α partly results from SA activity. In a recent 263 
review, Shara and Stohs (2015) came to the conclusion that the anti-inflammatory activity of SA is 264 
associated with down regulation of the pro-inflammatory effect of TNF-α. In addition to salicin, 265 
SA has other active compounds like polyphenols and flavonoids which may also play a role in the 266 
therapeutic action of SA (Dragos et al., 2017). On the other hand, HA didn’t seem to have any 267 
impact on the level of TNF-α in RA rats. Injection of intra-articular HA in rat antigen-induced 268 
arthritis did show no significant changes in the level of TNF-α in short-term and in long-term 269 
experiments (Roth et al., 2005). Thus, we suspect that SA has an important role in the anti-270 
inflammatory properties of a Glu+Hyal A+Sal treatment.  271 
At the end of the experiment, three treatments containing BS and/or SA were able to inhibit IL-17A 272 
expression compared to TNF-α that was only inhibited by Glu+Hyal A+Sal. Furthermore, we did 273 
not observe a difference in the level of TNF-α expression between the control and CFA group. 274 
These results suggest that TNF-α had a weaker role in chronic inflammation than IL-17A, at least 275 
at the sampling periods of our experimentation. IL-17A is also over-expressed in RA (Dudler et al., 276 
2000). It has been shown that TNF-α may be important in the onset of the arthritis induction, but it 277 
gradually loses its dominance with the progression of the inflammation (Joosten et al., 1996). They 278 
showed that anti-TNFα treatment was efficient shortly after the collagen-induced arthritis (CIA) in 279 
DBA/1 mice, reducing cartilage destruction, but that it had little effect when CIA is fully 280 
established (Joosten et al., 1996). To notice a difference in TNF-α levels, measurements should 281 
have then been performed at the beginning of the inflammatory phase. We suggest that TNF-α 282 
played  a lesser role in the late phase of our experiment and had lower involvement in inflammatory 283 
modulation than IL-1β and IL-17A.  284 
As mentioned previously, our treatments had a stronger impact on IL-17A expression than in the 285 
expression of the two other cytokines. IL-17 is involved in inflammation by stimulating other pro-286 
inflammatory cytokines and metalloproteinases in synoviocytes and chondrocytes (Dudler et al., 287 
2000). For example, it stimulates secretion of IL-1β and TNF-α by macrophages (Jovanovic et al., 288 
1998). Two studies came to the conclusion that arthritis treatments involving inhibition of IL-17 289 
could be as efficient as blocking IL-1 and TNF-α. They showed that IL-17 expression and activity 290 
is partly independent of these two cytokines under arthritis conditions (Koenders et al., 2005; 291 
Koenders et al., 2006). It can, for example, aggravate joint inflammation and cartilage destruction 292 
on its own without the increase of IL-1 or TNF-α. Also, blocking IL-1 in TNF-deficient mice was 293 
not sufficient to reduce IL-17 effects in streptococcal cell wall-induced (SCW) arthritis model 294 
(Koenders et al., 2006). IL-17 has the capacity to partly supplant the functions of IL-1 since these 295 
two have many overlapping responses and functions even if they are not from the same cytokine 296 
family, as shown in SCW-induced arthritis and IL-1-deficient mice (Koenders et al., 2005). We 297 
conclude that IL-17A might partly lead the inflammatory process at the end of our experimental 298 
arthritis and that treatments with plants were effective to decrease the expression of this cytokine. 299 
Anti-inflammatory properties of BS and SA successfully reduced the IL-17A effect according to 300 
our results.  301 
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Reactive oxygen species (ROS) can also contribute to matrix component degradation (Campo et 302 
al., 2008). ROS are generated at high rates in synovial neutrophils from RA patients (Sato et al., 303 
1988). Synovial fluid and HA are respectively susceptible to degradation and depolymerization by 304 
a high level of ROS (Sato et al., 1988). These processes promote loss of viscosity in the joint as 305 
well as osteoclast activation (Filippin et al., 2008). Different antioxidants (polyphenols, tannins, 306 
etc.) are found in natural ingredients (Sato et al., 1988) which have been reported to partly protect 307 
and limit damage to cartilage (Venkatesha et al., 2011). All combinations with HA, BS and/or SA 308 
have significantly increased the total antioxidant level in the plasma of our experimental rats. 309 
Combinations without SA appear to have more impact on antioxidant levels than those with SA. In 310 
a previous study, it has been demonstrated that CIA in rats increases the activity of three important 311 
enzymes involved in oxidative stress management in plasma: superoxide dismutase, glutathione 312 
peroxidase and catalase (Sharma et al., 2011). They showed that these enzymes respond naturally 313 
to a higher concentration of ROS after arthritis induction, increasing their activities to protect 314 
tissues in the joint. The antioxidant properties of biomolecules in the present study may have helped 315 
to attenuate oxidative stress. Another study demonstrated that GS reduces superoxide radicals in a 316 
dose-concentration manner which partly explains its antioxidant activity (Xing et al., 2009). 317 
Synovial fluid and endogenous HA usually protect the articular tissues from oxidative damage. 318 
Excessive ROS decrease the HA content of articulation while addition of exogenous HA can 319 
decrease ROS levels in synovial cells of RA and buffer the impact on HA oxidation and decline 320 
(Sato et al., 1988). It has also been observed that extract of BS has improved the antioxidant level 321 
in CIA rat models, significantly decreasing ROS (Umar et al., 2014). Salix nigra bark methanol 322 
extract has contributed to attenuate oxidative stress in CIA rats (Sharma et al., 2011). BS and SA 323 
also has a phenolic compound showing antioxidant activities (Kokkiripati et al., 2011; Dragos et 324 
al., 2017). We suggest that a combination of antioxidant properties of these natural ingredients 325 
increases the antioxidant capacity in plasma of our experimental rats. We also suggest that this rise 326 
in antioxidant capacity can partly be responsible for the reduction of the clinical signs of arthritis.   327 
Conclusion 328 
We conclude that the addition of Boswellia serrata and/or Salix alba attenuates clinical signs of 329 
rheumatoid arthritis in Freund’s complete adjuvant-induced arthritis in rats likely due to both their 330 
anti-inflammatory and antioxidant properties. Combinations with these plants have decreased hind-331 
paw swelling and improved arthritis scores. Our results on clinical symptoms have been confirmed 332 
by some of our molecular markers. Treatments with BS and/or SA help to reduce inflammation and 333 
cartilage degradation by reducing effectively IL-17A expression and to a lesser extent, the 334 
expression of IL-1β. BS and SA have helped to create a redox status that might buffer oxidative 335 
stress through higher antioxidant capacity in plasma. This capacity may be partly responsible for 336 
the amelioration of clinical symptoms of arthritis.  337 
Acknowledgements 338 
We are thankful to Samuel Fortin (Ph.D.) and Caroline Morin (Ph.D.) to their help for the 339 
familiarization with the arthritic model of Freund’s complete adjuvant.  340 
Funding 341 
This work was supported by the Industrial Research Assistance Program (IRAP) of National 342 
Research Council Canada (NRCC).  343 
.CC-BY-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a




Aghazadeh-Habashi, A., Gilzad Kohan, M.H., Asghar, W. & Jamali, F., 2014. Glucosamine 345 
Dose/Concentration-Effect Correlation in the Rat with Adjuvant Arthritis. J. Pharm. Sci. 103, 760-346 
767. 347 
Arthritis Society. Arthritis Type – Arthrose, Arthritis Society. [Consulted on April 18, 2018]. 348 
https://www.arthritis.ca/  349 
Butler, D.M., Maini, R.N., Feldmann, M. & Brennan, F.M., 1995. Modulation of proinflammatory 350 
cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti 351 
TNF-a antibody with interleukin1 receptor antagonist. Eur. Cytokine Netw. 6, 225-30. 352 
Campo, G.M., Avenoso, A., Campo, S., D'Ascola, A., Traina, P. & Calatroni, A., 2008. 353 
Chondroitin-4-sulphate inhibits NF-kB translocation and caspase activation in collagen-induced 354 
arthritis in mice. Osteoarthr. Cartilage 16, 1474-1483. 355 
Dragos, D., Gilca, M., Gaman, L., Vlad, A., Iosif, L., Stoian, I. & Lupescu, O., 2017. 356 
Phytomedicine in joint disorders. Nutrients 9, 70. 357 
Dudler, J., Renggli-Zulliger, N., Busso, N., Lotz, M. & So, A., 2000. Effect of interleukin 17 on 358 
proteoglycan degradation in murine knee joints. Ann. Rheum. Dis. 59, 529-532. 359 
Fan, A.Y., Lao, L., Zhang, R.X., Zhou, A.N., Wang, L.B., Moudgil, K.D., Lee, D.Y.W., Ma, Z.Z., 360 
Zhang, W.Y. & Berman, B.M., 2005. Effects of an acetone extract of Boswellia carterii Birdw. 361 
(Burseraceae) gum resin on adjuvant-induced arthritis in lewis rats. J. Ethnopharmacol. 101, 104-362 
109. 363 
Fazal, S.A., Khan, M., Nishi, S.E., Alam, F., Zarin, N., Bari, M.T & Ashraf, G.M., 2018. A clinical 364 
update and global economic burden of rheumatoid arthritis. Endocr. Metab. Immune Disord. Drug 365 
Tagets 18, 98-109. 366 
Filippin, L.I., Vercelino, R., Marroni, N.P. & Xavier, R.M., 2008. Redox signalling and the 367 
inflammatory response in rheumatoid arthritis. Clin. Exp. Immunol. 152, 415-422. 368 
Gaffen, S.L., 2009. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr. 369 
Rheumatol. Rep. 11, 365-370. 370 
Health Canada. Multiple ingredient joint health products, Health Canada. [Consulted on April 18, 371 
2018]. http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=multiple.joint.health&lang=eng 372 
Hua, J., Suguro, S., Hirano, S., Sakamoto, K. & Nagaoka, I., 2005. Preventive actions of a high 373 
dose of glucosamine on adjuvant arthritis in rats. Inflamm. Res. 54, 127-132. 374 
Joosten, L.A., Helsen, M., van de Loo, F.A. & van den Berg, W.B., 1996. Anticytokine treatment 375 
of established type II collagen–induced arthritis in DBA/1 mice: A comparative study using anti-376 
TNFα, anti–IL-1α/β, and IL-1Ra. Arthritis Rheumatol. 39, 797-809. 377 
Jovanovic, D.V., Di Battista, J.A., Martel-Pelletier, J., Jolicoeur, F.C., He, Y., Zhang, M., Mineau, 378 
F., & Pelletier, J.P., 1998. IL-17 stimulates the production and expression of proinflammatory 379 
cytokines, IL-β and TNF-α, by human macrophages. J. Immunol. 160, 3513–3521. 380 
Kaur, A., Nain, P., & Nain, J., 2012. Herbal plants used in treatment of rheumatoid arthritis: a 381 
review. Int. J. Pharm. Pharm. Sci. 4, 44-57. 382 
.CC-BY-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/325365doi: bioRxiv preprint first posted online May. 17, 2018; 
11 
 
Kimmatkar, N., Thawani, V., Hingorani, L. & Khiyani, R., 2003. Efficacy and tolerability of 383 
Boswellia serrata extract in treatment of osteoarthritis of knee - A randomized double blind placebo 384 
controlled trial. Phytomedicine 10, 3-7. 385 
Koenders, M.I., Lubberts, E., Oppers-Walgreen, B., van den Bersselaar, L., Helsen, M.M., Kolls, 386 
J.K., Joosten, L.A. & van den Berg, W.B., 2005. Induction of cartilage damage by overexpression 387 
of T cell interleukin-17A in experimental arthritis in mice deficient in interleukin-1. Arthritis 388 
Rheumatol. 52, 975–983. 389 
Koenders, M.I., Lubberts, E., van de Loo, F.A., Oppers-Walgreen, B., van den Bersselaar, L., 390 
Helsen, M.M., Kolls, J.K., Di Padova, F.E., Joosten, L.A. & van den Berg, W.B., 2006. Interleukin-391 
17 acts independently of TNF-α under arthritic conditions. J. Immunol. 176, 6262-6269. 392 
Kokkiripati, P.K., Bhakshu, L.M., Marri, S., Padmasree, K., Row, A.T., Raghavendra, A.S. & 393 
Tetali, S.D., 2011. Gum resin of Boswellia serrata inhibited human monocytic (THP-1) cell 394 
activation and platelet aggregation. J. Ethnopharmacol. 137, 893-901. 395 
Moreland, L.W., 2003. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of 396 
osteoarthritis: mechanisms of action. Arthritis Res. Ther. 5, 54-67. 397 
Reagan-Shaw, S., Nihal, M. & Ahmad, N., 2007. Dose translation from animal to human studies 398 
revisited. FASEB J. 22, 659–661. 399 
Roth, A., Mollenhauer, J., Wagner, A., Fuhrmann, R., Straub, A., Venbrocks, R.A., Petrow, P., 400 
Bräuer, R., Schubert, H., Ozegowski, J., Peschel, G., Müller, P.J. & Kinne, R.W., 2005. Intra-401 
articular injections of high-molecular-weight hyaluronic acid have biphasic effects on joint 402 
inflammation and destruction in rat antigen-induced arthritis. Arthritis Res. Ther. 7, R677-R686. 403 
Sato, H., Takahashi, T., Ide, H., Fukushima, T., Tabata, M., Sekine, F., Kobayashi, K., Negishi, M. 404 
& Niwa, Y., 1988. Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents 405 
of hyaluronic acid: Synovial fluid scavenging effect is enhanced in rheumatoid arthritis 406 
patients. Arthritis Rheumatol. 31, 63-71. 407 
Shara, M. & Stohs, S.J., 2015. Efficacy and safety of white willow bark (Salix alba) 408 
extracts. Phytother. Res. 29, 1112-1116. 409 
Sharma, S., Sahu, D., Das, H.R. & Sharma, D., 2011. Amelioration of collagen-induced arthritis 410 
by Salix nigra bark extract via suppression of pro-inflammatory cytokines and oxidative 411 
stress. Food Chem. Toxicol. 49, 3395-3406. 412 
Singh, S., Khajuria, A., Taneja, S.C., Khajuria, R.K., Singh, J. & Qazi, G.N., 2007. Boswellic acids 413 
and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats. Bioorg. 414 
Med. Chem. Lett. 17, 3706-3711. 415 
Umar, S., Umar, K., Sarwar, A.H.M.G., Khan, A., Ahmad, N., Ahmad, S., Katiyar, C.K., Husain, 416 
S.A. & Khan, H.A., 2014. Boswellia serrata extract attenuates inflammatory mediators and 417 
oxidative stress in collagen induced arthritis. Phytomedicine 21, 847-856. 418 
Venkatesha, S.H., Berman, B.M. & Moudgil, K.D., 2011. Herbal medicinal products target defined 419 
biochemical and molecular mediators of inflammatory autoimmune arthritis. Bioorgan. Med. 420 
Chem. 19, 21-29. 421 
Wandel, S., Jüni, P., Tendal, B., Nüesch, E., Villiger, P.M., Welton, N.J., Reichenbach, S. & Trelle, 422 
S., 2010. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or 423 
knee: network meta-analysis. Brit. Med. J. 341, c4675. 424 
.CC-BY-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/325365doi: bioRxiv preprint first posted online May. 17, 2018; 
12 
 
Xing, R., Liu, S., Wang, L., Cai, S., Yu, H., Feng, J. & Li, P., 2009. The preparation and antioxidant 425 
activity of glucosamine sulfate. Chin. J. Oceanol. Limn. 27, 283-287. 426 
Zheng, C.J., Zhao, X.X., Ai, H.W., Lin, B., Han, T., Jiang, Y.P., Xing, X. & Qin, L.P., 2014. 427 
Therapeutic effects of standardized Vitex negundo seeds extract on complete Freund's adjuvant 428 
induced arthritis in rats. Phytomedicine 21, 838-846. 429 
  430 
.CC-BY-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/325365doi: bioRxiv preprint first posted online May. 17, 2018; 
13 
 












DOSE FOR RAT (mg/kg 
corporeal) 




Hyaluronic acid (from bacterial 
fermentation) 200 21 
Extract of Boswellia serrata 
(normalized at 40% of boswellic 
acid) 
1000 103 
Salicine (active ingredient of 
Salix alba extract) 240 25 
 433 
Table 2. Primer sequences used for real-time PCR analysis. 434 
GENE  FORWARD PRIMER (5'-3') REVERSE PRIMER (5'-3') 
FRAGMENT 
LENGTH (base pair) 
 
IL-17A 1 GTGAGCCGGCAGAAGCAGGA GGCTCCGCCCAACCCAAGAT 107 
IL1-β 1 GGGATTTTGTCGTTGCTTGTC TGCAGGCTTCGAGATGAAC 147 
TNF-α 1 CTTCTGTCTACTGAACTTCGGG GCTACGGGCTTGTCACTC 146 
MMP 2 2 AGGAGGGCACTGGTGGCTCA GCCAGGGCAGCCGTAAGGGA 104 
MMP 9 1 GGAGACGGCAAACCCTGCGT GTGGTGGCGCACCAGCGATA 104 
MMP 13 1 AGCTTGGCCACTCCCTCGGT TGAACGTCATCATCTGGGAGCA 112 
β-actin 1,2 TCACTATCGGCAATGAGCG GGCATAGAGGTCTTTACGGATG 143 
GAPDH 1,2 GCCAAGGCTGTGGGCAAGGT GCAGGTTTCTCCAGGCGGCAT 119 
1 Amplification cycle: 1) initial activation at 95°C for 2 minutes, 2) 2-step: [95°C for 15 sec followed by 435 
60°C for 30 sec] X 40 amplification cycles. 436 
2 Amplification cycle: 1) initial activation at 95°C for 2 minutes, 2) 2-step: [95°C for 15 sec followed by 437 
63°C for 30 sec] X 40 amplification cycles. 438 
 439 
Fig 1. Temporal experimental plan of animal manipulations.  440 
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Fig 2. Effect of treatments on severity of arthritis. a) Hind paws thickness (mm) and b) arthritis 442 
score in time (number of arthritis post-induction days). Treatments have been daily administered 443 
starting at day 14 to day 29. Each circle is a mean ± SEM (control and CFA groups: n = 12; Glu: n 444 
= 11; Glu+Hyal A, Glu+Hyal A+Bosw, Glu+Hyal A+Sal, Glu+Bosw and Glu+Bosw+Sal: n = 6). 445 
Significant differences with CFA group (*) and control group (+) at day 29 are shown in a) p < 446 
0.05 and in b) p < 0.01.     447 
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Fig 3. Clinical condition of hind paws at the end of the experiment (after treatment of 15 days). 449 
Fig 4. Effect of treatments on genes expression of pro-inflammatory cytokines. Genes expression 450 
of a) IL-17A, b) IL-1β and c) TNF-α were measured in articular cartilage of hind paws at day 29 451 
(15e day of treatment). Each circle is a mean ± SEM (control and CFA groups: n = 10-12; Glu: n 452 
= 9-11; Glu+Hyal A, Glu+Hyal A+Bosw, Glu+Hyal A+Sal, Glu+Bosw and Glu+Bosw+Sal: n = 453 
5-6). Significant differences with CFA group (*) at day 29 are shown (p < 0.05).  454 
Control CFA Glu 
Glu + Hyal A + Sal Glu + Hyal A + Bosw 
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Fig 5. Effect of treatments on plasma content as total antioxidants. The content was measured in 455 
blood plasma at day 29 (15e day of treatment). Each circle is a mean ± SEM (control group: n = 8; 456 
CFA groups: n = 10-11; Glu: n = 9-10; Glu+Hyal A, Glu+Hyal A+Bosw, Glu+Hyal A+Sal, 457 
Glu+Bosw and Glu+Bosw+Sal: n = 5-6). Significant differences with CFA group (*) and control 458 
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